Evidence map›Paper›PMID 38435348›Full record

ArticleGynecologic oncology reports2024

Oxaliplatin desensitization for ovarian

Kaitlin Nicholson, Lily Jia, Margaret Rowe, Katharine Esselen, Naima Joseph, Chloe A Zera, Timothy Lax, Meghan Shea

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kaitlin NicholsonDepartment of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Lily JiaHarvard Medical School, Boston, MA, United States.
Margaret RoweDepartment of Medicine, Penn Medicine, Philadelphia, PA, United States.
Katharine EsselenDepartment of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Naima JosephDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Boston Medical Center/Boston University, Boston, MA, United States.
Chloe A ZeraDepartment of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Timothy LaxDepartment of Medicine, University of Massachusetts Memorial Health, Worcester, MA, United States.
Meghan SheaDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Beth Israel Deaconess Medical Center · USBoston University · USPenn Center for AIDS Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

•Incidence of cancer in pregnancy is rising and successful treatment of these patients requires expert multidisciplinary care.•Platinum hypersensitivity reactions in ovarian cancer are commonly treated with desensitization protocols.•To our knowledge, chemotherapy desensitization in pregnant patients has not been previously reported.•Oxaliplatin desensitization during pregnancy may be safe and feasible.

Indexed as

DesensitizationHypersensitivity reactionOvarian cancerPlatinum chemotherapy

Identifiers

PMID38435348
PMCPMC10909594
OpenAlexW4392262938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.